InvestSMART

Dimerix Limited (ASX: DXB) - Announcements

- Current share price for DXB : $0.250

ASX company news and announcements for Dimerix Limited (DXB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Dimerix Limited (DXB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Dimerix Limited (DXB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Dimerix Limited (DXB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$150 Quarterly Commentary & Appendix 4C 16 Jul 2019 9:31AM $0.100 $0.250 risen by 150%
$150 First DMX-200 Patents To Grant In Europe And Canada 11 Jul 2019 9:28AM $0.110 $0.250 risen by 127.27%
$150 DMX-200 Phase 2 Clinical Trial in FSGS Fully Recruited 10 Jul 2019 9:28AM $0.105 $0.250 risen by 138.10%
$150 Investor Presentation 26 Jun 2019 9:27AM $0.082 $0.250 risen by 204.88%
$150 DMX-200 Clinical Update 26 Jun 2019 9:23AM $0.082 $0.250 risen by 204.88%
$150 Dimerix Signs Licence Agreement for Receptor-HIT Technology 24 Jun 2019 9:38AM $0.074 $0.250 risen by 237.84%
$150 DMX-200 Manufacturing Update 27 May 2019 9:28AM $0.076 $0.250 risen by 228.95%
$150 CFO and Company Secretary Appointment/Resignation 6 May 2019 9:25AM $0.085 $0.250 risen by 194.12%
$150 Appendix 4C - quarterly 26 Apr 2019 12:10PM $0.089 $0.250 risen by 180.90%
$150 Appendix 3B 15 Mar 2019 6:59PM $0.086 $0.250 risen by 190.70%
$150 Trial Update Presentation 5 Mar 2019 8:23AM $0.084 $0.250 risen by 197.62%
$150 Half Year Report & DMX-200 Clinical Trials Update 26 Feb 2019 8:27PM $0.087 $0.250 risen by 187.36%
$150 Half Yearly Report and Accounts 26 Feb 2019 8:23PM $0.087 $0.250 risen by 187.36%
$150 Appendix 4C and Quarterly Highlights 31 Jan 2019 9:02AM $0.088 $0.250 risen by 184.09%
$150 Appendix 3B 29 Jan 2019 4:18PM $0.089 $0.250 risen by 180.90%
$150 Appendix 3B 14 Jan 2019 5:45PM $0.088 $0.250 risen by 184.09%
$150 Dimerix Receives R&D Tax Cash Rebate Totalling $1.07m 20 Dec 2018 9:37AM $0.088 $0.250 risen by 184.09%
$150 Change of Director's Interest Notice 27 Nov 2018 9:40AM $0.092 $0.250 risen by 171.74%
$150 Appendix 3B 27 Nov 2018 8:22AM $0.092 $0.250 risen by 171.74%
$150 Dimerix Awarded $50,000 Innovation Connections Grant 26 Nov 2018 9:18AM $0.093 $0.250 risen by 168.82%
$150 1st Patient Dosed in DMX-200 Clinical Trial for FSGS 22 Nov 2018 8:27AM $0.098 $0.250 risen by 155.10%
$150 DXB Receives Orphan Drug Designation in EU 21 Nov 2018 9:42AM $0.094 $0.250 risen by 165.96%
$150 Change of Address 12 Nov 2018 8:29AM $0.100 $0.250 risen by 150%
$150 Results of Meeting 30 Oct 2018 1:52PM $0.110 $0.250 risen by 127.27%
$150 AGM Presentation and CEO Address 30 Oct 2018 11:44AM $0.110 $0.250 risen by 127.27%

526 - 550 of 731 results

Page 22 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.